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Abstract
Background: Essential hypertension is a common, polygenic, complex disorder resulting from
interaction of several genes with each other and with environmental factors such as obesity, dietary
salt intake, and alcohol consumption. Since the underlying genetic pathways remain elusive,
currently most studies focus on the genes coding for proteins that regulate blood pressure as their
physiological role makes them prime suspects.
The present study examines how polymorphisms of the insertion/deletion (I/D) ACE and M235T
AGT genes account for presence and severity of hypertension, and embeds the data in a meta-
analysis of relevant studies.
Methods: The I/D polymorphisms of the ACE and M235T polymorphisms of the AGT genes were
determined by RFLP (restriction fragment length polymorphism) and restriction analysis in 638
hypertensive patients and 720 normotensive local blood donors in Weisswasser, Germany.
Severity of hypertension was estimated by the number of antihypertensive drugs used.
Results: No difference was observed in the allele frequencies and genotype distributions of ACE
gene polymorphisms between the two groups, whereas AGT TT homozygotes were more
frequent in controls (4.6% vs. 2.7%, P = .08). This became significant (p = 0.035) in women only.
AGT TT genotype was associated with a 48% decrease in the risk of having hypertension (odds
ratio: 0.52; 95% CI, 0.28 to 0.96), and this risk decreased more significantly in women (odds ratio:
0.28; 95% CI, 0.1 to 0.78). The meta-analysis showed a pooled odds ratio for hypertension of 1.21
(TT vs. MM, 95% CI: 1.11 to 1.32) in Caucasians. No correlation was found between severity of
hypertension and a specific genotype.
Conclusion: The ACE I/D polymorphism does not contribute to the presence and severity of
essential hypertension, while the AGT M235T TT genotype confers a significantly decreased risk
for the development of hypertension in the population studied here. This contrasts to the findings
of meta-analyses, whereby the T allele is associated with increased risk for hypertension.
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Background
Essential hypertension is a common, polygenic, complex
disorder resulting from interaction of several genes with
each other and with environmental factors such as obes-
ity, dietary salt intake, and alcohol consumption. Since
the underlying genetic pathways remain elusive[1], cur-
rently most studies focus on the genes coding for proteins
that regulate blood pressure as their physiological role
makes them prime suspects.
The Renin-Angiotensin System (RAS) has a central role in
regulating blood pressure and sodium homeaostasis.
Genes encoding components of RAS, including angi-
otensinogen (AGT), angiotensin-converting enzyme
(ACE), angiotensinogen II type-1 receptor (AGTR1), and
renin, have been extensively investigated as genetic deter-
minants of essential hypertension [2]. Polymorphisms of
RAS[3] genes seem also to play a role in the development
of diseases that cause secondary hypertension[4,5]. Sub-
jects carrying the ACE D allele have unanimously been
shown to have increased ACE serum activity[3,6] while
the T235 AGT variant has been associated with elevated
angiotensinogen levels [7]. However, so far there are no
consistent findings.
In 1992, the M235T AGT TT polymorphism was first
reported to be associated with hypertension [8]. This find-
ing has not been confirmed by all investigators[9,10].
Although no relationship between the ACE gene and
hypertension was observed in one early linkage study [11]
and most recent studies including one meta-analysis [12-
14], several studies have suggested a role: hypertensive
individuals have a high prevalence of the D allele or DD
genotype [3,15,16].
The inconsistent results might be explained in part by the
genetic and environmental heterogeneity among different
ethnic groups [13]. On the other hand, one recent study
[17] reported that the MM, AA, CC, DD/ID genotype com-
bination was associated with a substantially higher preva-
lence of hypertension in the participants to the Olivetti
Heart Study, even though no individual effect of each iso-
lated genotype was detected.
The present study investigates the relationship between
variants of the I/D ACE gene and M235T AGT gene, and
the presence and severity of essential hypertension in a
large homogeneous German population. The effect of a
combination of ACE and AGT gene polymorphisms on
hypertension was also examined.
Methods
Study design
The design of the study followed the guidelines proposed
by Cooper et al [18], and the study was carried out in
accordance with the Declaration of Helsinki [19].
Study population
This cross-sectional study comprised a total of 1358 indi-
viduals from Weisswasser, a county town of 25,000 in Sax-
ony, Germany. After giving informed consent, 720
normotensive subjects were selected from local blood
donors and 638 hypertensive patients from the local renal
care center. All hypertensive patients included in the study
had been diagnosed as suffering from primary hyperten-
sion by the attending consultants on first contact with the
clinic. Hypertensives were defined as those who received
at least one antihypertensive medication. At the time of
blood sampling, 34.2% were diabetic (6 type 1, 212 type
2), and 65.1% were suffering from kidney disease. Of the
37 patients with K/DOQI stage 5 (Kidney failure: GFR, 15
ml/min/1.73 m2 or dialysis), 15 were due to diabetic
nephropathy, 5 to chronic pyelonephritis, 1 to chronic
glomerulonephritis, 1 light chain deposits, 1 polycystic
kidney disease, and 14 of unknown cause (no biopsy
obtained). The severity of hypertension was estimated
based on the number of antihypertensive medications
used, a surrogate marker for the severity of hyperten-
sion[8]. Age and gender distribution is described in table
1.
Genotyping
RFLP (restriction fragment length polymorphism) and
restriction analysis were used to determine the frequencies
of the I/D polymorphisms of the ACE gene, and homo-/
heterozygoty of the M235T AGT gene[20,21]. ACE I/D
polymorphism was studied by PCR based amplification
of a 597 bp long gene fragment of the ACE gene, which
lacks 287 bp in case of the deletion (D) variant. The prim-
ers used were: sense-
5'GATGTGGCCATCACATTCGTCAGAT3', and antisense-
5'CTGGAGACCACTCCCATCCTTTCT3'.
AGT M235T polymorphism was studied by first amplify-
ing a 104 bp long fragment of the AGT gene using the fol-
lowing primer sequences: sense-
5'CCGTTTGTGCAGGGCCTGGCTCTCT3', and antisense:
5'CAGGGTGCTGTCCACACTGGACCCC3'.
The M -> T point mutation at position 235 creates a detec-
tion site for the restriction enzyme Tth 111I.
Statistical analysis
Statistical analysis was carried out using SPSS personal
computer statistical package (version 11.5, SSPS Inc, Chi-
cago, IL). Demographic characteristics were compared byBMC Nephrology 2005, 6:1 http://www.biomedcentral.com/1471-2369/6/1
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t test for continuous data and Pearson's χ2 test for categor-
ical data. Allele frequencies were calculated with the gene-
counting method. χ2 test was used for assessment of the
Hardy-Weinberg equilibrium for the distribution of geno-
types. Odds ratios were calculated with a 95% confidence
interval. A P < .05 was considered significant.
Meta-analysis
A meta-analysis was performed using Review Manager 4.2
(The Cochrane Collaboration) to further examine the
association of the AGT M235T gene polymorphisms with
essential hypertension in Caucasians. A systematic litera-
ture search in PubMed Medline for articles published
between April 2002 and June 2004 was carried out using
the following MESH-headings: "angiotensinogen/genet-
ics", "hypertension/genetics", "blood pressure/genetics",
and "adult". The search was limited to articles published
in English and studies on Caucasian human subjects.
Only 2 studies were left after strict examination according
to the exclusion criteria listed in [22]. A total of 25 studies
were finally included: 22 were from the most recent meta-
analysis [22], which covered articles from January 1992 to
March 2002; 2 were selected from the query described
above, and the last one was the present study. Homogene-
ity among studies was assessed on the basis of χ2 test using
P-value < 0.05. The Mantel-Haenszel odds ratios were cal-
culated by applying both fixed effect model and random
effect model in case of heterogeneity.
Results
Demographic data are summarized in Table 1. Hyperten-
sives were older (58.80 ± 13.22 years) than controls
(41.24 ± 12.66 years, p < .0001), and more often male
(53.2% vs. 44.4%, p = .001).
AGT M/T genotyping was successful in 637 hypertensives
and 720 normotensives, and ACE I/D genotype was ana-
lyzed in 636 hypertensive and 719 control subjects. The
roles of age and gender in the association between hyper-
tension and ACE and AGT gene polymorphisms were
examined by comparing the effects of ACE and AGT gen-
otypes for hypertension in men and women, young and
elderly subjects respectively. "Young" was defined as "age
< 50 years old", and "elderly" was characterized as "age ≥
50 years old".
ACE polymorphism
No differences were observed in ACE allele and genotype
frequency distribution between hypertensives and con-
trols with respect to gender and age, and no deviations
from Hardy-Weinberg equilibrium were observed in any
of subgroups (P > 0.1). ACE genotypes I/I, I/D and D/D
were of almost identical frequency within both groups (P
= 1.0, Figure 1). Risk assessment showed that there were
no significant risk changes for hypertension in the sub-
jects either with the ACE DD genotype (odds ratio: 1.00,
95% CI: 0.74 to 1.36, P = .98, Table 2) or D allele (odds
ratio: D vs. I: 1.00, 95% CI: 0.86 to 1.17, P = .98).
AGT polymorphism
AGT T/T homozygotes tended to be more frequent in con-
trols than in hypertensives (4.6% vs. 2.7%, Figure 2). In
women, this finding became significant (5.3% vs. 1.7%,
Figure 3), but no difference in AGT genotype frequency
was found in men. The distribution of the AGT genotypes
in all subgroups of the sample population was not in
Hardy-Weinberg equilibrium (P < .001). AGT TT genotype
was associated with a significant 48% decrease in the risk
of being hypertensive (Table 2, odds ratio: 0.52; 95% CI:
0.28 to 0.96; P = .034), and this risk decreased even more
to 72% in women (odds ratio: 0.28; 95% CI: 0.1 to 0.78;
P = .01). However, no difference was observed in the AGT
allele frequency distribution with respect to age and gen-
der (Table 3, P > 0.05), and the effect of the AGT T allele
did not reach a significant level in the decrease of hyper-
tension risk (odds ratio: T vs. M: 0.88; 95% CI: 0.75 to
1.03; P = .12).
Meta-analysis of studies on AGT polymorphisms in 
Caucasians
When all studies were pooled, Caucasian individuals with
TT genotype had an odds ratio for hypertension of
1.21(95% CI: 1.11 to 1.32) compared with those with
MM genotype (Figure 4). The studies included in the
meta-analysis are [8,20,23-43]. The pooled odds ratio
(odds ratio: TT vs. MM: 1.23; 95% CI: 1.13 to 1.34)
Table 1: Demographic features. M: male. F: female.
Hypertensives (n = 638) Normotensives (n = 720) P- value
Gender (M/F) 339/298 319/400 0.001
Age (yrs, + SD 58.80 ± 13.22 41.24 ± 12.66 < 0.001
Age < 50 yrs: n (%) 159 (24.9%) 547 (76.0%) < 0.001
Age > 50 yrs: n (%) 479 (75.1%) 173 (24.0%) < 0.001BMC Nephrology 2005, 6:1 http://www.biomedcentral.com/1471-2369/6/1
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ACE genotypes and allele frequencies, both genders combined Figure 1
ACE genotypes and allele frequencies, both genders combined. No significant differences. F(D): frequency of D- allele.
Table 2: Hypertension risks estimates for AGT and ACE genotypes by gender.
Odds ratio (95%CI)
MT vs. MM TT vs. MM ID vs. II DD vs. II MM DD/ID vs. Others MM II/ID vs. Others TT DD/ID vs. Others TT II/ID vs. Others
0.87 0.52 1 1 1.2 1.04 0.56 0.56
(0.69–1.09) (0.28–0.96)* (0.77–1.31) (0.74–1.36) (0.94–1.53) (0.81–1.34) (0.28–1.09) (0.28–1.12)
0.82 0.83 0.83 0.79 1 1.16 0.85 1.08
(0.59–1.15) (0.36–1.93) (0.57–1.21) (0.52–1.22) (0.76–1.43) (0.81–1.66) (0.34–2.11) (0.39–3.01)
0.88 0.28 1.26 1.32 1.45 0.97 0.33 0.31
(0.64–1.21) (0.10–0.78)* (0.85–1.85) (0.86–2.03) (1.04–2.02)* (0.69–1.37) (0.11–0.99)* (0.10–0.92)*
*P < 0.05; CI, confidence interval.BMC Nephrology 2005, 6:1 http://www.biomedcentral.com/1471-2369/6/1
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increased by 2.5% when the presented study was
excluded. Tests for heterogeneity were significant (P <
0.001) in the above two cases, and the odds ratios (TT vs.
MM) rose to 1.30 (95% CI: 1.10 to 1.54), and 1.35 (95%
CI: 1.15 to 1.59) respectively when applying the random
effects model.
Combination of ACE and AGT polymorphisms
The effect of eight combinations (TT, DD/ID; TT, II/ID;
MM, DD/ID; MM, II/ID; DD MM/MT; DD, TT/MT; II,
MM/MT; II, TT/MT) on hypertension was examined. No
statistically significant association was observed between
any combination above and hypertension in all subjects
combined. Nonetheless, in women, both genotypes of TT,
DD/ID and TT, II/ID were significantly associated with
lower prevalence of hypertension (Table 2, 20% vs.
43.3%, odds ratio: 0.33, P = 0.038; 19% vs.43.6%, odds
ratio: 0.31, P = 0.026), while MM, DD/ID genotype
significantly increased the risk for hypertension (Table 2,
49.2% vs. 40.1%, odds ratio: 1.45, P = 0.028).
No association could be identified between severity of
hypertension and a specific ACE or AGT genotype (Table
4).
Discussion
Although some recent studies [15,16,44,45] suggested a
unique sex-specific role of ACE in essential hypertension,
AGT genotypes and allele frequencies, both genders combined Figure 2
AGT genotypes and allele frequencies, both genders combined. No significant differences. F(T): frequency of T- allele.BMC Nephrology 2005, 6:1 http://www.biomedcentral.com/1471-2369/6/1
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AGT genotypes and allele frequencies in women (significant at p = 0.035) Figure 3
AGT genotypes and allele frequencies in women (significant at p = 0.035). F(T): frequency of T- allele.
Table 3: AGT T allele frequencies by age and gender.
f(T)
Hypertensives (n) Normotensives (n) P- value
Age < 50 yrs 0.36 (159) 0.36 (547) NS
Age ≥ 50 yrs 0.32 (479) 0.37 (173) NS
Male 0.35 (339) 0.37 (319) NS
Female 0.32 (298) 0.36 (400) NS
Total 0.33 (638) 0.36 (720) NS
f(T), frequency of AGT T allele; NS, not significant; yrs, years.BMC Nephrology 2005, 6:1 http://www.biomedcentral.com/1471-2369/6/1
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no significant association of essential hypertension with
the ACE gene I/D polymorphism was observed in this
German population of 1,358 for either gender. This
finding confirms earlier observations in another German
population [31], in other Caucasian populations
[11,12,14,46], and in one meta-analysis [13]. The distri-
bution of the ACE genotypes was in Hardy-Weinberg
equilibrium in this German population while that was
not the case in Pereira et al's study [1]. One possible expla-
nation is the ethnic difference. Pereira et al. [1] showed
that there were statistically different ACE I/D polymor-
phism genotypic frequencies in different ethnic groups.
Surprisingly, the cross-sectional study presented here
shows a higher prevalence of the T/T M235T AGT gene in
the control group compared to the hypertensive group.
AGT TT genotype was associated with a decrease in the risk
for hypertension (odds ratio-TT vs. MM: 0.52; 95% CI:
0.28 to 0.96) and a more significant association was
found in women (odds ratio-TT vs. MM: 0.28; 95% CI: 0.1
to 0.78), compared to men. This is in stark contrast to
findings from previous studies, including two German
datasets [31,32], and three meta-analyses [10,22,47],
which reported that the AGT  235 T-allele and/or TT
genotype significantly increased  the risk for essential
Risk of hypertension associated with the AGT M235T genotypes in Caucasians Figure 4
Risk of hypertension associated with the AGT M235T genotypes in Caucasians.
Table 4: Prevalence of ACE and AGT genotypes by severity of hypertension.
ACE Genotype n (%) AGT Genotype n (%)
II ID DD P- value MM MT TT P- value
Hypertensive, one drug 56 (22) 120 (48) 74 (30) 0.458 83 (33) 163 (65) 5 (2) 0.225
Hypertensive, > two drugs 89 (24) 189 (51) 93 (25) 0.458 142 (38) 217 (59) 12 (3) 0.225BMC Nephrology 2005, 6:1 http://www.biomedcentral.com/1471-2369/6/1
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hypertension in Caucasians: odds ratio T vs. M was 1.20
(95% CI: 1.11 to 1.29) [10], odds ratio TT vs. MM was
1.31 [47], and odds ratio TT vs. MM was 1.19 (95% CI:
1.10 to 1.30)[22]. In agreement with the previous meta-
analyses, the meta-analysis presented here showed
increased odds for hypertension (odds ratio: TT vs. MM:
1.21) in Caucasians conferred by TT, and the odds ratio
rose by 2.5% when the present study was excluded. Of the
25 studies included in the present meta-analysis, the
present study was the only one in which the AGT T235T
genotype decreased odds for hypertension. Nevertheless,
the quality of meta-analysis results depends on the quality
of the individual studies included, and unusual sample
sizes might bias the finding. For example, one single study
[43] included in the previously largest meta-analysis [22]
was exceptionally large, giving it enormous weight. The
highly variable study quality implies that all interpreta-
tions must be made with great caution, as was explicitly
pointed out by Kunz et al. [10]
Although no significant difference was observed in AGT T
allele frequency distribution between hypertensives and
controls with respect to age and gender, the frequency of
the AGT T allele among normotensives was higher than
that among hypertensives (0.36 vs. 0.33). This was incon-
sistent with one previous meta-analysis in Caucasians,
which showed that among controls, the mean allele
frequency for the AGT T allele was 0.41 (95% CI: 0.34 to
0.48), and among cases, increased to 0.45 (95% CI: 0.38
to 0.52) [10]. In the present study, the frequency of the
AGT T allele among hypertensives (0.33) was outside the
lower border of the 95% confidence interval (0.38 to
0.52) reported in [10]. This may reveal the specific genetic
background of this particular German population.
The AGT genotype distribution is not in Hardy-Weinberg
equilibrium (P < 0.001) while no deviations from Hardy-
Weinberg equilibrium are observed on the ACE genotype
distribution in the same population. This may be
explained by a shift toward a higher frequency of MT
individuals (62.4%) instead of TT individuals (3.7%) in
this specific population.
The study population presented here contains a large pro-
portion (65%) of patients with renal disease. While selec-
tion of participants based on patient records excluded
those patients that had symptoms suggesting the diagno-
sis of secondary hypertension at first contact, the possibil-
ity remains that at least a part of the study population
suffers from renal rather than essential hypertension. It
should be noted, however, that the majority of studies
included in the presented meta-analysis does not give spe-
cific information regarding renal function of hyperten-
sives, and the largest study [43] is population based and
does not name any specific, kidney related exclusion
criteria.
Another possible explanation is that the AGT T allele fre-
quency may decrease with age, which was reported from
the United Arab Emirates [48]. The prevalence of hyper-
tension increases with advancing age. According to the
National Health and Nutrition Examination Survey III
(NHANES III) prevalence estimates for the years 1988–
1994, American Whites aged 55 to 64 years have a more
than threefold higher prevalence of hypertension (42.1%)
than those aged 35 to 44 years (11.3%) [49]. Frossard et
al detected that AGT T allele frequency decreased with age
in the United Arab Emirates[48]. The ACE DD genotype
was found associated with human longevity [50]. In the
present study, normotensives are significantly younger
than hypertensives (41 ± 12 yrs vs. 59 ± 13 yrs). It is con-
ceivable that many of the young individuals are at hyper-
tension risk because of their ACE or AGT genotype, but
have not yet shown hypertension at the time of genotyp-
ing, and may develop hypertension in their older age. This
might lead to some misclassifications and hence reduce
the power of this study. On the other hand, two studies of
German populations [32,51] reported that the AGT T
allele was a risk factor for hypertension in individuals
younger than 50 years of age. In the present study, young
hypertensives had a higher frequency of the AGT T allele
than elderly hypertensives (0.36 vs. 0.32), but the differ-
ence didn't reach statistical significance (p = .22). It is
possible that the small percentage (24.9%) of the studied
hypertensives under 50 years of age biased the finding.
A number of studies [51-54] examined the relationship
between RAS genotype and the severity of hypertension,
but their results were contradictory. In accordance with
two [52,54] of them including one German dataset, the
present study fails to find an effect of the AGT or ACE gen-
otype on the severity of hypertension. Nevertheless, in the
present study, hypertensives that carried at least one copy
of the AGT T allele (TT or MT: n = 397) were less likely to
take two or more antihypertensive medications than those
with MM genotype (n = 225) (odds ratio -TT or MT vs.
MM: 0.797; 95% CI: 0.57 to 1.12; P = .185), and their
average number of antihypertensive drugs was lower
(2.09 vs. 2.20; P = .276). Despite not reaching statistical
significance, this observation was in contrast to Schunkert
et al's study [51] on another German population (subjects
initially participated in the MONICA Augsburg cohort
baseline survey), which found that the carriers of the AGT
T allele (n = 418) had a 2.1-fold higher probability of tak-
ing two or more antihypertensive drugs than individuals
with the MM genotype (n = 216). It is worth pointing out
that in the present study, the number of subjects taking
antihypertensive medications is much larger than in
Schunkert et al's study (622 vs. 143). While the data is farBMC Nephrology 2005, 6:1 http://www.biomedcentral.com/1471-2369/6/1
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from statistical significance, the trend is in line with those
findings that associate rather the M allele with hyperten-
sion in the present study.
The effect of a combination of RAAS genes' polymor-
phisms on blood pressure has been investigated in the
participants to the Olivetti Heart Study [17], in which the
MM, AA, CC, DD/ID genotype was detected to be associ-
ated with a substantially higher prevalence of hyperten-
sion in the absence of detectable effects of each individual
polymorphism at any single locus. The present study
showed very similar findings in women: MM, DD/ID gen-
otype significantly increased the odds for hypertension
(odds ratio: 1.45; 95% CI: 1.04 to 2.02), while TT, DD/ID
and TT, II/ID were significantly associated with lower
prevalence of hypertension (odds ratio: 0.33, 95% CI:
0.11 to 0.99; odds ratio: 0.31, 95% CI: 0.10 to 0.92). The
risk of hypertension in the women with TT, DD/ID and
TT, II/ID, however, didn't change much compared with
those with TT alone (odds ratio: 0.31, 95% CI: 0.12 to
0.83). This suggests that there is only a slight synergistic
effect between the AGT and ACE genes.
Although in most surveys the prevalence of hypertension
appears to be equal in women and men [55], sex-specific
effects of ACE or AGT genes on hypertension have been
reported recently [16,43]. For instance, Sethi et al. [43]
found the AGT TT associated with an increase in risk for
hypertension in women but not in men from the Copen-
hagen City Heart Study with a population of 9100 sub-
jects, and an association of the ACE DD genotype with
increased diastolic blood pressure was detected in men,
but not in women from the Framingham Heart Study
[16]. In the present study, the AGT TT genotype was nega-
tively correlated to hypertension in women only while no
sex-specific effect of the ACE gene was shown. It is
possible that the fact is covered by the different gender dis-
tributions: in this population, there are more women in
normotensives than in hypertensives (55.6% vs. 46.8%, P
= .001).
In addition to the factor declared above, the result may be
influenced by the study design and the composition of the
sample population. The study design itself may influence
the results. As mentioned above, this study was a cross-
sectional study where subjects were assessed at a single
time, and at that time most of the controls were younger
than 50 years old. Animal studies have shown that hyper-
tension genes may be activated for only certain periods
during the life history of an organism [2]. Hence, some of
them might develop hypertension at an older age, result-
ing from the activated hypertension genes. Longitudinal
studies are needed to further examine the relationship
between hypertension and genes at different ages.
The population can be described as static population with
a mixed Germanic-Slavonic background. Due to the loca-
tion (a provincial town on the German-Polish border)
and political and historical setting (little population fluc-
tuation during the over 140 years of imperial, fascist and
socialist rule, no influx due to lack of economic attractiv-
ity after reunification), the population may be assumed as
homogeneous. Several recent studies [56-61] have
reported significant differences in prevalence of
hypertension between Germany and Poland, which, how-
ever, are assumed to be largely dependent on life-style dif-
ferences, mostly salt intake. These differences, however,
are unlikely to play a role in the study population due to
its homogeneity with regards to life style preferences fol-
lowing successful assimilation over many generations. In
the case of ACE polymorphism with all allele frequencies
greater than 15%, there is no need to examine population
stratification [62]. This becomes more urgent for AGT
where there is no Hardy- Weinberg equilibrium. As the
sample information, however, does not include data on
the ethnic background of the probands, additional haplo-
typing carried out on the samples would not have allowed
to rectify for the historical ethnic background (Germanic
versus Slavonic).[62,63]
In the meantime, it should be noted that the present study
was carried out on an unusually large population (second
only to one in 63 studies included in Sethi's meta-analy-
sis[22]). Given the large homogeneous population-based
sample, the findings cannot be attributed to simple selec-
tion bias. Therefore, the finding that the AGT TT genotype
associated with a decreased risk for essential hypertension
is likely to be true for this particular German population.
Conclusions
Despite the limitations mentioned, this cross-sectional
study does not support the notion that the ACE I/D poly-
morphism contributes to the prevalence and severity of
essential hypertension. However, the M235T TT genotype
of AGT gene was detected to confer a significantly
decreased risk for the prevalence of hypertension in
women from this particular population. Despite the large
sample size, the present study fails to revise the odds ratio
in a meta-analysis of a total of 25 studies on the
association between the AGT M235T polymorphisms and
hypertension in caucasians. This observation may reflect a
very specific local inheritance pattern of the AGT geno-
types. If this holds true, studies aiming at drug develop-
ment based on genomic traits must be scrutinized
rigorously as therapeutic recommendations may be valid
for selected subpopulations only[64].
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